Adams Respiratory Therapeutics, Inc. 4
4 · Adams Respiratory Therapeutics, Inc. · Filed Jul 28, 2005
Insider Transaction Report
Form 4
Transactions
- Conversion
Common Stock, par value $0.01 per share
2005-07-26+3,619,690→ 5,177,604 total - Conversion
Series B Convertible Preferred Stock
2005-07-26−3,619,690→ 0 total→ Common Stock (3,619,690 underlying) - Sale
Common Stock
2005-07-26$15.81/sh−1,609,000$25,438,290→ 5,088,376 total - Conversion
Common Stock
2005-07-26+1,519,772→ 6,697,376 total - Conversion
Series C Convertible Preferred Stock
2005-07-26−1,519,772→ 0 total→ Common Stock (1,519,772 underlying)
Footnotes (4)
- [F1]All of the securities reported herein are held for the account of Perseus-Soros BioPharmaceutical Fund, LP ("Perseus-Soros"). Perseus-Soros Partners, LLC, a Delaware limited liability company ("Perseus-Soros Partners"), is the general partner of Perseus-Soros. Perseus BioTech Fund Partners, LLC, a Delaware limited liability company ("Perseus Partners"), and SFM Participation, L.P., a Delaware limited partnership ("SFM Participation"), are the managing members of Perseus-Soros Partners. Perseuspur, L.L.C., a Delaware limited liability company ("Perseuspur"), is the managing member of Perseus Partners.
- [F2]Mr. Frank Pearl ("Mr. Pearl") is the sole member of Perseuspur and in such capacity may be deemed a beneficial owner of securities held for the account of Perseus-Soros. SFM AH, LLC, a Delaware limited liability company ("SFM AH"), is the general partner of SFM Participation. The sole managing member of SFM AH is Soros Fund Management LLC, a Delaware limited liability company ("SFM LLC"). Mr. George Soros ("Mr. Soros") is the Chairman of SFM LLC and in such capacity may be deemed a beneficial owner of securities held for the account of Perseus-Soros.
- [F3]All of the outstanding shares of the Issuer's Series B Convertible Preferred Stock automatically converted on a 1-for-1 basis into common stock immediately prior to the Issuer's initial public offering.
- [F4]All of the outstanding shares of the Issuer's Series C Convertible Preferred Stock automatically converted on a 1-for-1 basis into common stock immediately prior to the Issuer's initial public offering.